dChan
Anonymous ID: 74442f May 29, 2020, 2:23 p.m. No.9366316   🗄️.is 🔗kun   >>6380 >>6529 >>6635 >>6720

Sanofi sold Regeneron Pharma through a secondary offering: $11.702b-May 29

 

And under-written by the usual suspects

 

Regeneron Pharmaceuticals : Completes Secondary Offering of Common Stock Held by Sanofi

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the secondary offering of 13,014,646 shares of its common stock held by Sanofi, which includes the exercise in full of the underwriters' option to purchase additional shares from Sanofi, at a public offering price of $515.00 per share. The Company also announced the completion of its repurchase of 9,806,805 shares directly from Sanofi at a price of $509.85 per share (representing the price paid by the underwriters in the offering), for an aggregate purchase amount of $5 billion. Pursuant to the offering and repurchase, Sanofi has disposed of all of its shares of common stock in Regeneron, other than 400,000 shares that it is retaining.

 

Regeneron did not receive any of the proceeds from the sale of shares of its common stock by Sanofi. The public offering occurred simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs & Co. LLC, together with Barclays, BNP Paribas, Citigroup, J.P. Morgan, Morgan Stanley as joint book-running managers.

https://www.marketscreener.com/REGENERON-PHARMACEUTICALS-10649/news/Regeneron-Pharmaceuticals-Completes-Secondary-Offering-of-Common-Stock-Held-by-Sanofi-30695035/

 

Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows:

  • sales of products (61.5%);

  • supply of collaborative services (33.3%): working with Sanofi (54.5% of sales) and Bayer (45.5%);

  • sales of technology licenses (5.2%). The group also provides subcontracting research services.

 

At the end of 2019, the group had a portfolio of 22 products in clinical development. Number of employees : 8 100 people.

 

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:

 

  • pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs;

 

  • human vaccines (15.9%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.

 

At the end of 2019, the group had 81 production sites throughout the world.

 

Net sales are distributed geographically as follows: Europe (24.5%), United States (35.3%), Asia (12.2%), Latin America (7.6%), Africa and Middle East (6.4%) and other (14%).

 

Number of employees : 100 409 people.

https://www.marketscreener.com/SANOFI-SA-4698/company/

 

https://www.finviz.com/insidertrading.ashx?oc=1121404&tc=7&b=2